Supporting publications

The following publications may provide additional data to help you learn more about ZEGERID, the First and Only Immediate-Release Oral PPI, now available in Capsules and Powder for Oral Suspension.

Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin. Pharmacother. 2005; 6(14):2501-2510.

Order full article from PubMed
Request article from Santarus Medical Affairs

Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of omeprazole immediate-release Powder for Oral Suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastroesophageal reflux disease. Aliment Pharmacol Ther 2005; 21:1467-74.

Order full article from PubMed
Request article from Santarus Medical Affairs

Conrad S, Gabrielli A, Margolis B, Quartin A, Hata J, Frank W, Bagin R, Rock J, Hepburn B, Laine L. A randomized double-blind comparison of immediate-release omeprazole oral suspension vs. intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33:760-765.

Order full article from PubMed
Request article from Santarus Medical Affairs

Katz PO. Nocturnal reflux: assessing and addressing the problem. Practical Gastroenterology 2005; 30-39.

Request article from Santarus Medical Affairs [NOT AVAILABLE ON PUBMED]

Small RE. Advances in proton-pump inhibitor therapy: an immediate-release formulation of omeprazole. Pharmacy and Therapeutics 2005; 30 (12):698-713.

Request article from Santarus Medical Affairs [NOT AVAILABLE ON PUBMED]

Peura D. Clinical implications of immediate-release PPI therapy in the management of GERD and upper GI bleeding. Introduction. Aliment Pharmacol Ther 2005; 22 (S3):1-1.

Order full article from PubMed
Request article from Santarus Medical Affairs

Kahrilas PJ, Pandolfino, JE. Review article: oesophageal pH monitoring – technologies, interpretation and correlation with clinical outcomes. Aliment Pharmacol Ther 2005; 22 (S3): 2-9.

Order full article from PubMed
Request article from Santarus Medical Affairs

Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005; 22 (s3):10-19.

Order full article from PubMed
Request article from Santarus Medical Affairs

Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005; 22 (S3):20-24.

Order full article from PubMed
Request article from Santarus Medical Affairs

Howden CW. Review article: immediate-release proton-pump inhibitor therapy – potential advantages. Aliment Pharmacol Ther 2005; 22 (S3):25-30.

Order full article from PubMed
Request article from Santarus Medical Affairs

Katz PO. Review article: putting immediate-release proton-pump inhibitors into clinical practice – improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther 2005; 22 (S3):31- 38.

Order full article from PubMed
Request article from Santarus Medical Affairs

Fennerty MB. Review article: alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther 2005; 22 (S3):39-44.

Order full article from PubMed
Request article from Santarus Medical Affairs

Maton PN. Review article: prevention of stress-related mucosal bleeding with proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 (s3):45-52.

Order full article from PubMed
Request article from Santarus Medical Affairs

Triadafilopoulos G. Review article: the role of antisecretory therapy in the management of non-variceal upper gastrointestinal bleeding. Aliment Pharmacol Ther 2005; 22 (S3):53-58.

Order full article from PubMed
Request article from Santarus Medical Affairs

Next page: Gastroenterology/PCP meetings calendar

About ZEGERID | Is ZEGERID Right For Your Patients? | Patient Tools
Physician Resources | Important Safety Information

Please see full prescribing information.

You can obtain additional information about ZEGERID by writing Santarus directly. To speak to a representative by phone or to report an adverse event, call Santarus' Medical Information Department at 1.888.778.0887, option 2 (M-F, 9:00 am to 7:00 pm, EST).

Product Description
ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus protects omeprazole from acid degradation.

Indications and Dosing for ZEGERID
ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
(20 mg); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy
(20 mg); for maintenance of healing of erosive esophagitis (20 mg) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg; use beyond 14 days has not been evaluated).

Important Safety Information about ZEGERID
The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In 178 critically ill patients treated with ZEGERID Powder for Oral Suspension, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID Powder for Oral Suspension than in those treated with the comparator (acid-controlling) drug. For more information about these and other events, please see Table 13 of the Full Prescribing Information. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

ZEGERID Capsules contain 304 mg of sodium per dose. ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose. This should be taken into consideration for patients on a sodium-restricted diet.

Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules,
1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.